Dair Sansyzbayev | PFE | PFE:CA Pfizer: I Should Have Sold Earlier (Downgrade) ByMario Cazombo June 3, 2025
ALT | BioCGT Investor | PFE | PFE:CA | VKTX Altimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover Potential ByMario Cazombo June 2, 2025
ALNY | Edmund Ingham | NTLA | PFE | PFE:CA | REGN Intellia: Heart Disease Safety Setback Triggers Selloff –Â Caution Advised ByMario Cazombo May 29, 2025
ALNY | BBIO | ELAM1 Consulting | PFE | PFE:CA Why Alnylam Could Outperform In The Transthyretin Amyloidosis With Cardiomyopathy Field ByMario Cazombo May 29, 2025
Oakoff Investments | PFE | PFE:CA Unlocking Pfizer’s Value: Cost Controls And Oncology Pipeline ByMario Cazombo May 28, 2025
ALLKA Research | ALPMF | ALPMY | BMY | BMYMP | CELG.RT | DSKYF | DSNKY | GLAXF | GSK | MRK | MRK:CA | PFE | PFE:CA | SPY Merck Proves Why It’s Still A Top Pharma Pick ByMario Cazombo May 27, 2025
ALLKA Research | BMY | BMYMP | CELG.RT | CYTK | JPM | JPM:CA | JPM.PR.C | JPM.PR.D | JPM.PR.J | JPM.PR.K | JPM.PR.L | JPM.PR.M | MRK | MRK:CA | PFE | PFE:CA | RDY | TEVA | TEVJF Bristol-Myers Squibb At ASCO 2025: A Resilient Play Amid Market Turbulence ByMario Cazombo May 27, 2025
JR Research | LLY | LLY:CA | NONOF | NVO | NVON:CA | PFE | PFE:CA | VKTX Viking Therapeutics: Buy It For The Future And Ignore The Noise ByMario Cazombo May 27, 2025
